Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR). What Happened: According to Reuters, Pfizer Inc (NYSE:PFE) won the bidding war against Novo Nordisk and will purchase Metsera for $10 billion. The board of Me... Read more
Benzinga - Nov 11
global obesity therapeutics market size reached US$ 9.19 Billion in 2023 with a rise of US$ 11.03 Billion in 2024 and is expected to reach US$ 63.75 Billion by 2033, growing at a CAGR of 21.6% during the forecast period Read more
Openpr.com - Nov 10Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral and injectable treatments for obesity and diabetes. On Friday, Metsera announced that Pfizer will acqu... Read more
Apnews - Nov 08
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. Read more
The New York Times - Nov 08
Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50. • Watch the MTSR momentum here.Metsera said the amended proposal constitutes a “Superior Company Proposal.”Additionally, Metsera... Read more
Benzinga - Nov 04
Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine. Read more
Euronews - Sep 22
